| Literature DB >> 18330611 |
Valentina Curigliano1, Maria Giovinale, Claudia Fonnesu, Claudia Cerquaglia, Elena Verrecchia, Simona Turco, Chiara Manganelli, Raffaele Manna.
Abstract
Behçet's disease is a systemic inflammatory disorder without a specific treatment that is chosen on the basis of the type and severity of manifestation in the organ involved. More recently, biological agents like etanercept have emerged as possible therapeutic alternatives in patients resistant to conventional therapy. We describe the successful treatment for 1 year of resistant Behçet's disease with etanercept. After the administration of this drug, a resolution of the clinical, laboratory and instrumental picture was achieved with a suspension of immunosuppressive treatments and a reduction of steroid dependency (5 mg/day). No side effects were observed.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18330611 DOI: 10.1007/s10067-008-0857-5
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 2.980